Literature DB >> 33793745

Carbon tattooing for targeted lymph node biopsy after primary systemic therapy in breast cancer: prospective multicentre TATTOO trial.

S Hartmann1, T Kühn2, J de Boniface3,4, A Stachs1, A Winckelmann2, J Frisell4, I Wiklander-Bråkenhielm5, J Stubert1, B Gerber1, T Reimer1.   

Abstract

BACKGROUND: Several techniques for targeted lymph node biopsy in patients with node-positive breast cancer receiving primary systemic therapy are in use, each with their inherent advantages and disadvantages. The aim of the TATTOO trial was to evaluate the feasibility and accuracy of carbon tattooing of positive lymph nodes as a method for targeted lymph node biopsy avoiding radiation exposure, high costs, and preoperative localization procedures.
METHODS: Patients with initially cT1-4c cN1-3 cM0 invasive breast cancer were included in this prospective multicentre trial. Before initiation of primary systemic therapy, a carbon suspension was injected into the most suspicious axillary lymph node. Targeted lymph node biopsy was performed in all patients after completion of primary systemic therapy. Additional sentinel lymph node biopsy was done in those with axillary downstaging, and completion axillary lymph node dissection in patients still presenting with suspicious lymph nodes.
RESULTS: A total of 118 patients were included and 110 were eligible for data analysis. The detection rate for the targeted lymph node was 93.6 per cent (103 of 110), and the sentinel lymph node was identical to the targeted lymph node in 60 per cent. The false-negative rate for the combination of targeted and sentinel node lymph node biopsy (targeted axillary dissection) was 9 per cent.
CONCLUSION: Targeted axillary dissection after carbon tattooing is associated with a high detection rate, an acceptable false-negative rate, and appears feasible for clinical use even in healthcare settings with limited resources.
© The Author(s) 2021. Published by Oxford University Press on behalf of BJS Society Ltd. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Entities:  

Year:  2021        PMID: 33793745     DOI: 10.1093/bjs/znaa083

Source DB:  PubMed          Journal:  Br J Surg        ISSN: 0007-1323            Impact factor:   6.939


  4 in total

1.  False-negative rate in the extended prospective TATTOO trial evaluating targeted axillary dissection by carbon tattooing in clinically node-positive breast cancer patients receiving neoadjuvant systemic therapy.

Authors:  Jana de Boniface; Jan Frisell; Thorsten Kühn; Ingrid Wiklander-Bråkenhielm; Karin Dembrower; Per Nyman; Athanasios Zouzos; Bernd Gerber; Toralf Reimer; Steffi Hartmann
Journal:  Breast Cancer Res Treat       Date:  2022-04-22       Impact factor: 4.624

2.  Pathological Response in the Breast and Axillary Lymph Nodes after Neoadjuvant Systemic Treatment in Patients with Initially Node-Positive Breast Cancer Correlates with Disease Free Survival: An Exploratory Analysis of the GeparOcto Trial.

Authors:  Bernd Gerber; Andreas Schneeweiss; Volker Möbus; Michael Golatta; Hans Tesch; David Krug; Claus Hanusch; Carsten Denkert; Kristina Lübbe; Jörg Heil; Jens Huober; Beyhan Ataseven; Peter Klare; Markus Hahn; Michael Untch; Karin Kast; Christian Jackisch; Jörg Thomalla; Fenja Seither; Jens-Uwe Blohmer; Kerstin Rhiem; Peter A Fasching; Valentina Nekljudova; Sibylle Loibl; Thorsten Kühn
Journal:  Cancers (Basel)       Date:  2022-01-20       Impact factor: 6.639

3.  Axillary Staging after Neoadjuvant Chemotherapy for Initially Node-Positive Breast Carcinoma in Germany: Initial Data from the AXSANA study.

Authors:  Steffi Hartmann; Thorsten Kühn; Michael Hauptmann; Elmar Stickeler; Marc Thill; Michael P Lux; Sarah Fröhlich; Franziska Ruf; Sibylle Loibl; Jens-Uwe Blohmer; Hans-Christian Kolberg; Elisabeth Thiemann; Michael Weigel; Christine Solbach; Gabriele Kaltenecker; Peter Paluchowski; Michael G Schrauder; Stefan Paepke; Dirk Watermann; Markus Hahn; Maria Hufnagel; Jutta Lefarth; Michael Untch; Maggie Banys-Paluchowski
Journal:  Geburtshilfe Frauenheilkd       Date:  2022-09-13       Impact factor: 2.754

4.  The Clinical Relevance of Target Lymph Node Biopsy after Primary Systemic Therapy in Initially Node-Positive Breast Cancer Patients.

Authors:  Steffi Hartmann; Angrit Stachs; Gesche Schultek; Bernd Gerber; Toralf Reimer
Journal:  Cancers (Basel)       Date:  2021-05-26       Impact factor: 6.639

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.